Organic cation transporter OCT/SLC22A and H(+)/organic cation antiporter MATE/SLC47A are key molecules for nephrotoxicity of platinum agents.

Platinum agents have been widely used in cancer chemotherapy for a long time. Cisplatin, carboplatin, oxaliplatin and nedaplatin have a common chemical structure consisting of platinum, carrier groups and leaving groups, and undergo the similar mechanism of cytotoxicity. However, each agent differs in its efficacy and adverse effects, although the molecular mechanism involved is unclear. Recently, it was reported that organic cation transporter OCT/SLC22A, and multidrug and toxin extrusion MATE/SLC47A play a role in the pharmacokinetics of platinum agents. Only cisplatin induces nephrotoxicity and the toxicity is kidney-specific. Kidney-specific OCT2 mediates the transport of cisplatin and is the determinant of cisplatin-induced nephrotoxicity. In addition, cisplatin and oxaliplatin are substrates for these transporters, but carboplatin and nedaplatin are not. Substrate specificity could regulate the features of platinum agents. In this commentary, we will discuss the characteristics of OCT and MATE, and demonstrate the recent topics about the relationship between the transport of platinum agents by organic cation transporters and their pharmacological characteristics.

[1]  M. Weiner,et al.  Mechanism of cis-platinum nephrotoxicity: II. Morphologic observations. , 1980, The Journal of pharmacology and experimental therapeutics.

[2]  M. Takano,et al.  Carrier-mediated transport systems of tetraethylammonium in rat renal brush-border and basolateral membrane vesicles. , 1984, Biochimica et biophysica acta.

[3]  Hiroshi Omote,et al.  A human transporter protein that mediates the final excretion step for toxic organic cations. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[4]  M. Weiner,et al.  Renal handling of cis-diamminedichloroplatinum(II). , 1980, Cancer treatment reports.

[5]  Z. Siddik,et al.  The comparative pharmacokinetics of carboplatin and cisplatin in mice and rats. , 1987, Biochemical pharmacology.

[6]  K. Inui,et al.  Oppositely directed H+ gradient functions as a driving force of rat H+/organic cation antiporter MATE1. , 2007, American journal of physiology. Renal physiology.

[7]  A. Yonezawa,et al.  Disruption of multidrug and toxin extrusion MATE1 potentiates cisplatin-induced nephrotoxicity. , 2010, Biochemical pharmacology.

[8]  B. Blair,et al.  The Role of the Mammalian Copper Transporter 1 in the Cellular Accumulation of Platinum-Based Drugs , 2009, Molecular Pharmacology.

[9]  A. Guarino,et al.  Distribution and disposition of platinum following intravenous administration of cis-diamminedichloroplatinum(II) (NSC 119875) to dogs. , 1976, Cancer research.

[10]  Bing Zhou,et al.  hCTR1: a human gene for copper uptake identified by complementation in yeast. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[11]  Stephen B. Howell,et al.  Cisplatin Rapidly Down-regulates Its Own Influx Transporter hCTR1 in Cultured Human Ovarian Carcinoma Cells , 2004, Clinical Cancer Research.

[12]  S. Masuda,et al.  Cisplatin and Oxaliplatin, but Not Carboplatin and Nedaplatin, Are Substrates for Human Organic Cation Transporters (SLC22A1–3 and Multidrug and Toxin Extrusion Family) , 2006, Journal of Pharmacology and Experimental Therapeutics.

[13]  Hideyuki Saito,et al.  Gene expression levels and immunolocalization of organic ion transporters in the human kidney. , 2002, Journal of the American Society of Nephrology : JASN.

[14]  P. Daley-Yates,et al.  The mechanism of renal clearance of cisplatin (cis-dichlorodiammine platinum ii) and its modification by furosemide and probenecid. , 1982, Biochemical pharmacology.

[15]  H. Koepsell,et al.  Carriers involved in targeting the cytostatic bile acid-cisplatin derivatives cis-diammine-chloro-cholylglycinate-platinum(II) and cis-diammine-bisursodeoxycholate-platinum(II) toward liver cells. , 2002, Molecular pharmacology.

[16]  Satohiro Masuda,et al.  Involvement of Human Multidrug and Toxin Extrusion 1 in the Drug Interaction between Cimetidine and Metformin in Renal Epithelial Cells , 2009, Journal of Pharmacology and Experimental Therapeutics.

[17]  V. Ganapathy,et al.  Cloning and Functional Characterization of a Potential-sensitive, Polyspecific Organic Cation Transporter (OCT3) Most Abundantly Expressed in Placenta* , 1998, The Journal of Biological Chemistry.

[18]  J. Bonventre,et al.  Acute renal failure. , 2018, The New England journal of medicine.

[19]  S. Masuda,et al.  Differential contribution of organic cation transporters, OCT2 and MATE1, in platinum agent-induced nephrotoxicity. , 2007, Biochemical pharmacology.

[20]  H. Koepsell,et al.  Drug excretion mediated by a new prototype of polyspecific transporter , 1994, Nature.

[21]  M. J. van den Bent,et al.  Weekly high-dose cisplatin is a feasible treatment option: analysis on prognostic factors for toxicity in 400 patients , 2003, British Journal of Cancer.

[22]  Tomoko Sato,et al.  Transcellular transport of organic cations in double-transfected MDCK cells expressing human organic cation transporters hOCT1/hMATE1 and hOCT2/hMATE1. , 2008, Biochemical pharmacology.

[23]  Shuzhong Zhang,et al.  Organic cation transporters are determinants of oxaliplatin cytotoxicity. , 2006, Cancer research.

[24]  R. Murphy,et al.  The copper transporter Ctr1 contributes to cisplatin uptake by renal tubular cells during cisplatin nephrotoxicity. , 2009, American journal of physiology. Renal physiology.

[25]  E. Berns,et al.  Differential transport of platinum compounds by the human organic cation transporter hOCT2 (hSLC22A2) , 2010, British journal of pharmacology.

[26]  S. Masuda,et al.  Association between tubular toxicity of cisplatin and expression of organic cation transporter rOCT2 (Slc22a2) in the rat. , 2005, Biochemical pharmacology.

[27]  H. Koepsell,et al.  Organic cation transporter 2 mediates cisplatin-induced oto- and nephrotoxicity and is a target for protective interventions. , 2010, The American journal of pathology.

[28]  Stephen G Aller,et al.  Projection structure of the human copper transporter CTR1 at 6-A resolution reveals a compact trimer with a novel channel-like architecture. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[29]  I. Wallin,et al.  Cimetidine as an organic cation transporter antagonist. , 2010, The American journal of pathology.

[30]  A. Schinkel,et al.  Deficiency in the Organic Cation Transporters 1 and 2 (Oct1/Oct2 [Slc22a1/Slc22a2]) in Mice Abolishes Renal Secretion of Organic Cations , 2003, Molecular and Cellular Biology.

[31]  T. Mizuno,et al.  Targeted Disruption of the Multidrug and Toxin Extrusion 1 (Mate1) Gene in Mice Reduces Renal Secretion of Metformin , 2009, Molecular Pharmacology.

[32]  M. Takano,et al.  cDNA cloning and functional expression of a novel rat kidney organic cation transporter, OCT2. , 1996, Biochemical and biophysical research communications.

[33]  M. Gottesman,et al.  The role of cellular accumulation in determining sensitivity to platinum-based chemotherapy. , 2008, Annual review of pharmacology and toxicology.

[34]  J. Bull,et al.  Kinetics of cis‐dichlorodiammineplatinum , 1979, Clinical pharmacology and therapeutics.

[35]  M. Hedeland,et al.  Oxaliplatin Degradation in the Presence of Chloride: Identification and Cytotoxicity of the Monochloro Monooxalato Complex , 2004, Pharmaceutical Research.

[36]  J. Nielsen,et al.  Renal handling of carboplatin , 2004, Cancer Chemotherapy and Pharmacology.

[37]  J. Doroshow,et al.  Oxaliplatin Pharmacokinetics and Pharmacodynamics in Adult Cancer Patients with Impaired Renal Function , 2007, Clinical Cancer Research.

[38]  B. Sikic,et al.  Pharmacokinetics and protein binding of cis-dichlorodiammine platinum (II) administered as a one hour or as a twenty hour infusion , 2004, Cancer Chemotherapy and Pharmacology.

[39]  S. Masuda,et al.  Protective effect of concomitant administration of imatinib on cisplatin-induced nephrotoxicity focusing on renal organic cation transporter OCT2. , 2009, Biochemical pharmacology.

[40]  Thomas Ludwig,et al.  Nephrotoxicity of platinum complexes is related to basolateral organic cation transport. , 2004, Kidney international.

[41]  I. Herskowitz,et al.  Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[42]  Hiroaki Yuasa,et al.  The Inhibition of Human Multidrug and Toxin Extrusion 1 Is Involved in the Drug-Drug Interaction Caused by Cimetidine , 2009, Drug Metabolism and Disposition.

[43]  K. Inui,et al.  Reduced Renal Clearance of a Zwitterionic Substrate Cephalexin in Mate1-Deficient Mice , 2010, Journal of Pharmacology and Experimental Therapeutics.

[44]  O. Ogawa,et al.  Identification and functional characterization of a new human kidney-specific H+/organic cation antiporter, kidney-specific multidrug and toxin extrusion 2. , 2006, Journal of the American Society of Nephrology : JASN.

[45]  A. Guarino,et al.  Pharmacokinetic study of cis-dichlorodiammineplatinum(II) (DDP) in the beagle dog: thermodynamic and kinetic behavior of DDP in a biologic millieu. , 1979, Cancer treatment reports.

[46]  Dong Wang,et al.  Cellular processing of platinum anticancer drugs , 2005, Nature Reviews Drug Discovery.

[47]  H. Koepsell,et al.  Polyspecific Organic Cation Transporters: Structure, Function, Physiological Roles, and Biopharmaceutical Implications , 2007, Pharmaceutical Research.

[48]  K. Nugent,et al.  Cisplatin Nephrotoxicity: A Review , 2007, The American journal of the medical sciences.

[49]  A. Sparreboom,et al.  Contribution of Organic Cation Transporter 2 (OCT2) to Cisplatin‐Induced Nephrotoxicity , 2009, Clinical pharmacology and therapeutics.

[50]  K. Inui,et al.  Physiological and pharmacokinetic roles of H+/organic cation antiporters (MATE/SLC47A). , 2008, Biochemical pharmacology.

[51]  Z. Siddik,et al.  Pharmacokinetics of cis-diammine-1,1-cyclobutane dicarboxylate platinum(II) in patients with normal and impaired renal function. , 1984, Cancer research.

[52]  H. Pinedo,et al.  Interaction of cisplatin and carboplatin with sodium thiosulfate: reaction rates and protein binding. , 1986, Clinical chemistry.

[53]  T. Ludwig,et al.  Cisplatin nephrotoxicity is critically mediated via the human organic cation transporter 2. , 2005, The American journal of pathology.

[54]  D. Lydall,et al.  Mechanism of cytotoxicity of anticancer platinum drugs: evidence that cis-diamminedichloroplatinum(II) and cis-diammine-(1,1-cyclobutanedicarboxylato)platinum(II) differ only in the kinetics of their interaction with DNA. , 1986, Cancer research.

[55]  Z. Siddik,et al.  Role of human copper transporter Ctr1 in the transport of platinum-based antitumor agents in cisplatin-sensitive and cisplatin-resistant cells. , 2004, Molecular cancer therapeutics.

[56]  S. Masuda,et al.  Cellular and molecular aspects of drug transport in the kidney. , 2000, Kidney international.

[57]  W. Hiddemann,et al.  Oxaliplatin pharmacokinetics during a four-hour infusion. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[58]  F. Lang,et al.  Cloning and characterization of two human polyspecific organic cation transporters. , 1997, DNA and cell biology.

[59]  J. Verweij,et al.  Interaction of Cisplatin with the Human Organic Cation Transporter 2 , 2008, Clinical Cancer Research.

[60]  M. Okuda,et al.  Cisplatin-induced toxicity in LLC-PK1 kidney epithelial cells: role of basolateral membrane transport. , 1999, Toxicology Letters.